Bulletin
Investor Alert

New York Markets Open in:

press release

Feb. 3, 2022, 7:31 a.m. EST

Revolution Medicines to Participate in Guggenheim Healthcare Talks 2022 Oncology Conference

REDWOOD CITY, Calif., Feb 03, 2022 (GLOBE NEWSWIRE via COMTEX) -- REDWOOD CITY, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. /zigman2/quotes/216320743/composite RVMD -2.32% , a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that the company will participate in the Guggenheim Healthcare Talks 2022 Oncology Conference. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a fireside chat at the event.

Details of the company's participation are as follows:

  • Guggenheim Healthcare Talks 2022 Oncology ConferenceConference Date: February 9-11, 2022
    Fireside Chat Time/Date: 12:30 p.m. Pacific on Thursday, February 10, 2022
    Format: Virtual conference; webcast available

To access the live webcast of the fireside chat, please visit the "Events & Presentations" page of Revolution Medicines' website at https://ir.revmed.com/events-and-presentations . Additionally, a replay of the webcast will be available on the "Events & Presentations" page of the Revolution Medicines website for at least 14 days following the conference.

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors in development include RMC-6236 (RAS [MULTI] ), RMC-6291(KRAS [G12C] ), RMC-9805 (KRAS [G12D] ) and RMC-8839 (KRAS [G13C] ), and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).







        Contacts:
        For Investors:
        Vida Strategic Partners
        Stephanie Diaz
        415-675-7401
        sdiaz@vidasp.com
        
        For Media:
        Vida Strategic Partners
        Tim Brons
        415-675-7402
        tbrons@vidasp.com
        


COMTEX_401700819/2471/2022-02-03T07:30:42

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

(C) Copyright 2022 GlobeNewswire, Inc. All rights reserved.

/zigman2/quotes/216320743/composite
US : U.S.: Nasdaq
$ 24.40
-0.58 -2.32%
Volume: 1.27M
Aug. 8, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$2.14 billion
Rev. per Employee
$142,750
loading...

Partner Center

Link to MarketWatch's Slice.